All In Biotech

Drug Trial Radar · NCT06730750

A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

A Phase 1/2a, Multicenter, Open-label, First in Human Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 360 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

360

Planned (sponsor's estimate)

Start

Feb 12, 2025

Primary completion

Sep 5, 2026

Study completion Dec 9, 2029

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Dec 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study of BMS-986490 as a monotherapy and in combination with bevacizumab in participants with select advanced solid tumors known to express CEACAM5.

Conditions

  • Advanced Solid Tumors

Interventions

  • BMS-986490Drug

    Specified dose on specified days.

  • BevacizumabDrug

    Specified dose on specified days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participnats with Adverse Events (AEs)Time frame: Up to 100 days following discontinuation of dosing
  2. Number of participants with Serious AEs (SAEs)Time frame: Up to 100 days following discontinuation of dosing
  3. Number of participants with AEs meeting protocol-defined dose limiting toxicity (DLT) criteriaTime frame: Up to 28 days after the first treatment of study intervention
  4. Number of participants with AEs leading to discontinuationTime frame: Up to 100 days following discontinuation of dosing
  5. Number of deathsTime frame: Up to 100 days following discontinuation of dosing

Locations

6 sites in 3 countries. Site status is shown where the registry gives one.

  • Local Institution - 0007

    Los Angeles, California

  • Local Institution - 0017

    Grand Rapids, Michigan

  • Local Institution - 0004

    Hackensack, New Jersey

  • Local Institution - 0006

    Pittsburgh, Pennsylvania

  • Tasman Oncology Research

    Southport, Queensland, Australia

  • Local Institution - 0003

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.